NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase

Compound: 6-shogaol

Targets

Gene Name

Gene ID

Cancer

Cell Lines

IC₅₀

ED₅₀

EC₅₀

GI₅₀

Remark

References

VEGFA

vascular endothelial growth factor A

7422

Ovarian Cancer

A-2780

-

-

-

-

6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).

18096028

VEGFA

vascular endothelial growth factor A

7422

Ovarian Cancer

CaOV3

-

-

-

-

6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).

18096028

VEGFA

vascular endothelial growth factor A

7422

Ovarian Cancer

SK-OV-3

-

-

-

-

6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).

18096028

VEGFA

vascular endothelial growth factor A

7422

Ovarian Carcinoma

ES-2

-

-

-

-

6-shogaol treatment resulted in inhibition of VEGF secrettion. Inhibition of VEGF secretion was most evident in the ES-2 cell line (p = .007), as compared to the other cell lines tested (p = .19, .18, and .07 for A2780, CaOV3, andSKOV3 respectively).

18096028

Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.